| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3734 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3756 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3756 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3756 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3756 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3756 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3756 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3772 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |
| 0003-3774 | OPDIVO | nivolumab | E.R. Squibb & Sons, L.L.C. | BLA | Current |